Physician profile
Celeste E Case
NPI 1639194301
$1,745.95
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $182 · 2021: $302 · 2022: $199.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $271.80 | 2019-2022 | |
| Allergan, INC. | $254.35 | 2019-2021 | |
| Emd Serono, INC. | $238.20 | 2019 | |
| Genentech USA, INC. | $164.57 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $155.63 | 2019-2020 | |
| Abbvie INC. | $123.21 | 2022 | |
| Alexion Pharmaceuticals, INC. | $109.64 | 2019 | |
| Lundbeck LLC | $105.60 | 2019-2021 | |
| Biogen, INC. | $84.66 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $60.33 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $35.76 | 2019-2021 | |
| Neurelis, INC. | $27.82 | 2021 | |
| Piramal Critical Care | $22.99 | 2020 | |
| Acadia Pharmaceuticals INC | $18.78 | 2020 | |
| Csl Behring | $18.49 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.79 | 2019 | |
| Sk Life Science, INC. | $13.43 | 2021 | |
| Saol Therapeutics INC. | $12.57 | 2020 | |
| Celgene Corporation | $12.33 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.